This is a research study to test a new drug called NMRA-323511 for its safety and effects on elderly people and adults with dementia, specifically from Alzheimer's disease. The study has two parts. In Part A, healthy older adults aged 65 to 80 will participate. In Part B, adults aged 55 to 90 with Alzheimer's-related agitation will join. Randomized means participants are randomly chosen to receive either the drug or a placebo (a "fake" treatment to compare results). The study is double-blind, meaning neither the participants nor the researchers know who gets the actual drug, to ensure fairness. Placebo-controlled means some people will get the placebo to compare against those receiving the active drug.
- Part A: Includes a screening (up to 28 days), 10-day treatment, and a follow-up visit.
- Part B: Includes a screening (up to 28 days), 8-week treatment, and a follow-up visit.
- Participants must meet specific health criteria and age requirements.
The study aims to improve treatments for Alzheimer's agitation. It's important to read the eligibility criteria carefully and consider possible risks before joining.